Document Detail


Extranuclear signaling by estrogen: role in breast cancer progression and metastasis.
MedLine Citation:
PMID:  21079578     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The estrogen receptor (ERa) is implicated in the progression of breast cancer. Hormonal therapies which block ER functions or local and systemic estrogen production are currently used to treat ERa positive breast cancer. Hormonal therapy shows beneficial effects, however, initial or acquired resistance to endocrine therapies frequently occurs, and tumors recur as metastasis. Emerging evidence suggests in addition to exerting its well-studied nuclear functions, ERa also participates in extranuclear signaling that involve growth factor signaling components, adaptor molecules and the stimulation of cytosolic kinases. ERa extranuclear pathways have the potential to activate gene transcription, modulate cytoskeleton, and promote tumor cell proliferation, survival, and metastasis. Cytoplasmic/membrane ERa is detected in a subset of breast tumors and expression of extranuclear components ERa is deregulated in tumors. The extranuclear actions of ER are emerging as important targets for tumorigenic and metastatic control. Inhibition of ERa extranuclear actions has the potential to prevent breast tumor progression and may be useful in preventing ERa positive metastasis. In this review, we summarize the results of recent research into the role of ERa mediated extranuclear actions in breast tumorigenesis and metastasis.
Authors:
V Cortez; M Mann; D W Brann; R K Vadlamudi
Related Documents :
15387438 - A recombinant cell bioassay for measurement of overall estrogenic activity of serum: pr...
11382148 - 1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for...
19154418 - Chicken ovalbumin upstream promoter transcription factor ii in human breast carcinoma: ...
10399488 - [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum(ii)--pharma...
8522248 - Dna amplification of her-2/neu and int-2 oncogenes in epithelial ovarian cancer.
22815728 - Birth weight, breast cancer and the potential mediating hormonal environment.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Minerva ginecologica     Volume:  62     ISSN:  0026-4784     ISO Abbreviation:  Minerva Ginecol     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-16     Completed Date:  2011-05-06     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  0400731     Medline TA:  Minerva Ginecol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  573-83     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Hormonal / therapeutic use
Breast Neoplasms / drug therapy,  genetics*,  pathology,  secondary*
Disease Progression
Estrogen Receptor alpha / genetics*
Female
Humans
Neoplasm Invasiveness
Neoplasm Metastasis
Receptors, Estrogen / genetics
Signal Transduction / genetics*
Treatment Outcome
Tumor Markers, Biological / genetics
Grant Support
ID/Acronym/Agency:
5R01NS050730/NS/NINDS NIH HHS; CA095681/CA/NCI NIH HHS; R01 CA095681/CA/NCI NIH HHS; R01 CA095681-08/CA/NCI NIH HHS; R01 CA095681-08S1/CA/NCI NIH HHS; R01 NS050730/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Estrogen Receptor alpha; 0/Receptors, Estrogen; 0/Tumor Markers, Biological; 0/estrogen receptor alpha, human
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  MicroRNAs in breast cancer pathogenesis.
Next Document:  Breast cancer during pregnancy: a literature review.